Skip to content

Vaxcyte

US · PCVX #1630 by market cap Listed 2020
55.39 -2.97 -5.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 21 in the most recent period (2026/Q3).
  • Total institutional ownership fell 4.2 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
112.85% -4.23pp
Institutions
434 +21
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund84.82%
Hedge Fund11.79%
VC/PE Fund11.58%
Public Company2.32%
Sovereign Wealth Fund0.79%
Individual/Insider0.59%
Government Pension Fund0.54%
Private Company0.52%
Insurance Company0.26%

Top holders as of 2026-10-31

T. Rowe Price Group, Inc. 13.35% · 21.13M sh
FMR 13.17% · 20.85M sh
Janus Henderson Group plc 11.40% · 18.04M sh
BlackRock 7.69% · 12.18M sh
RA Capital Management, L.P. 7.25% · 11.47M sh
Wellington Management Group 4.42% · 7.00M sh
Vanguard Capital Management, LLC 4.15% · 6.57M sh
Vanguard Portfolio Management, LLC 4.15% · 6.57M sh
State Street Global Advisors 3.31% · 5.23M sh
Deep Track Capital, LP 2.72% · 4.30M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 16 buys · 33 sells

NameRoleStake
Grant Pickering Chief Executive Officer 0.36%
James Wassil Executive VP, Chief Scientific Officer & COO 0.09%
Andrew Guggenhime President 0.07%
Harpreet Dhaliwal -- 0.01%
Heath Lukatch Former Independent Director 0.01%
Elvia Cowan Senior VP of Finance & Chief Accounting Officer 0.01%
Carlos Paya Independent Chairperson 0.01%
Teri Loxam Independent Director 0.01%
Halley Gilbert Independent Director 0.01%
Annie Drapeau Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Harpreet Dhaliwal -- Derivative Exercise and Sale -17,000 $24.79–68.82
2026-11-01 James Wassil Executive VP, Chief Scientific Officer & COO Derivative Exercise and Sale -2,250 $5.35–61.57
2026-11-01 Elvia Cowan Senior VP of Finance & Chief Accounting Officer Derivative Exercise and Sale -3,000 $25.92–61.55
2026-10-04 James Wassil Chief Operating Officer Intent to Sell (Form 144) -18,000 $86.74
2026-10-04 James Wassil Executive VP, Chief Scientific Officer & COO Derivative Exercise and Sale -18,000 $5.35–86.74
2026-10-04 Elvia Cowan Senior VP of Finance & Principal Accounting Officer Intent to Sell (Form 144) -19,000 $86.74
2026-10-04 Elvia Cowan Senior VP of Finance & Chief Accounting Officer Derivative Exercise and Sale -19,000 $25.92–86.74
2026-09-30 James Wassil Executive VP, Chief Scientific Officer & COO Derivative Exercise and Sale -2,250 $5.35–57.09
2026-09-08 James Wassil Executive VP, Chief Scientific Officer & COO Automatic Disposition -2,715 $59.52–61.16
2026-09-08 James Wassil Executive VP, Chief Scientific Officer & COO Intent to Sell (Form 144) -1,334 $59.99
2026-09-07 Andrew Guggenhime President Sale to Issuer -7,155 $60.36
2026-09-07 Grant Pickering Chief Executive Officer Sale to Issuer -17,056 $60.36
2026-09-07 James Wassil Executive VP, Chief Scientific Officer & COO Sale to Issuer -5,459 $60.36
2026-09-07 Elvia Cowan Senior VP of Finance & Chief Accounting Officer Sale to Issuer -1,327 $60.36
2026-09-07 Harpreet Dhaliwal -- Sale to Issuer -7,651 $60.36
2026-09-03 James Wassil Executive VP, Chief Scientific Officer & COO Intent to Sell (Form 144) -1,381 $59.73
2026-09-03 Luis Jodar Chief Medical Officer Other Acquisition +52,632 --
2026-09-03 Luis Jodar Chief Medical Officer Other Derivative Acquisition +88,254 $61.16
2026-09-01 Andrew Guggenhime President Sale to Issuer -2,705 $60.74–61.58
2026-09-01 Grant Pickering Chief Executive Officer Sale to Issuer -6,289 $60.74–61.58

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vaxcyte discussion 0 comments

Add a comment